Regeneron Pharmaceuticals (REGN) Short-term Investments (2009 - 2026)

Regeneron Pharmaceuticals' Short-term Investments history runs 18 years deep, the most recent figure standing at $5.8 billion for Q1 2026.

• On a quarterly basis, Short-term Investments rose 10.11% year-over-year to $5.8 billion in Q1 2026; TTM through Mar 2026 was $5.8 billion, a 10.11% increase from a year earlier, with the FY2025 full-year figure at $5.5 billion, down 15.9% from the prior year.
• Short-term Investments climbed to $5.8 billion in Q1 2026 per REGN's latest filing, from $5.5 billion in the prior quarter.
• Across five years, Short-term Investments topped out at $8.1 billion in Q4 2023 and bottomed at $3.5 billion in Q3 2022.
• The 5-year median for Short-term Investments is $5.8 billion (2026), against an average of $6.0 billion.
• Across the five-year window, Short-term Investments jumped 126.87% in 2022 and sank 33.57% in 2025, its largest moves.
• Year by year, Short-term Investments stood at $4.6 billion in 2022, then jumped by 75.02% to $8.1 billion in 2023, then declined by 19.6% to $6.5 billion in 2024, then slipped by 15.9% to $5.5 billion in 2025, then gained by 5.54% to $5.8 billion in 2026.
• Per Business Quant, the three latest REGN Short-term Investments figures stand at $5.8 billion (Q1 2026), $5.5 billion (Q4 2025), and $5.9 billion (Q3 2025).